Table 2.

Outcomes of NUP98-rearranged hematological malignancy

Tumor	Age	No. of patients		Fusion partner	Outcome	Reference
		Total	Fusion
AML	Pediatric	124	6	NSD1	33.3% 4-y EFS and OS	59
AML	Pediatric	246	15	NSD1	13%, 52%, 81% 3-y EFS, OS, CIR, respectively	32
AML	Pediatric	181	25	NSD1	25% and 33% EFS with and without FLT3 alteration, respectively	33
AML	Pediatric	98	18	Mostly NSD1 (also KDM5A, TOP1)	30% and 48% 5-y DFS and OS, respectively	31
AML	Pediatric	385	10	9 NSD1, 1 KDM5A	10% and 25% EFS and OS, respectively	60
AML	<3 y	232	6	KDM5A	33.3%, 16.7%, 83.3% 3-y OS, EFS, CIR, respectively	61
AEL	Pediatric	35	7	5 KDM5A, 2 NSD1	∼35% 5-y OS	3
AMKL	Pediatric	87	5	KDM5A	35%, 25%, 62% 5-y OS, EFS, CIR, respectively	62
AMKL	Pediatric	153	14	KDM5A	36%, 36%, 36% 4-y OS, EFS, CIR, respectively	63
FLT3-ITD+ AML	Pediatric	44	8	NSD1	4% complete response rate	64
AML	Pediatric	238	12	NSD1	31%, 8%, 83% 4-y OS, EFS, CIR, respectively	34
AML	Adult	727	9	NSD1	11%, 0%, 89% 4-y OS, EFS, CIR, respectively	34
AML	Pediatric	2381	46	KDM5A	34%, 30%, 64% 4-y OS, EFS, RR, respectively	55
AML	Adult	17	16	HOXA9	4-mo median DFS, 8-mo median OS	65
AML	Adult	493	11	HOXA9	13.5-mo median OS, 6-mo median DFS	66
AML	Adult	257	6	NSD1	1.8-mo median EFS	67
AML	Younger adult, <60 y	504	7	NSD1	43% complete response rate	68

AEL, acute erythroid leukemia; AMKL, acute megakaryoblastic leukemia; CIR, cumulative incidence of relapse; DFS, disease-free survival; EFS, event-free survival; OS, overall survival; RR, relapse rate.